Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Announces ILUVIEN® Now Available In U.K.

PR Newswire April 29, 2013

Alimera Sciences Reports Fourth Quarter 2012 Financial Results

PR Newswire March 21, 2013

Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results

PR Newswire March 11, 2013

Alimera Sciences' ILUVIEN® Receives Final Published Guidance From U.K.'s NICE

PR Newswire January 23, 2013

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Spain For The Treatment Of Chronic Diabetic Macular Edema

PR Newswire January 17, 2013